11:23 AM EDT, 03/25/2026 (MT Newswires) -- (Updates with replies from CVS Health ( CVS ) and the FTC in the third and fourth paragraphs.)

CVS Health ( CVS ) has reached a proposed settlement with the Federal Trade Commission over insulin pricing, Reuters reported Tuesday, citing the company.

The company's pharmacy benefit management unit, Caremark, has focused on lowering prescription drug costs, CVS said, adding that the settlement is expected to be finalized in the coming weeks, with final terms still pending, according to the report.

"We are pleased to have a proposed settlement agreement in place with the FTC staff," CVS Health ( CVS ) told MT Newswires, adding that the proposed deal still needs approval from the FTC chair, and more details will be disclosed after the review.

In a reply to MT Newswires, the FTC shared a court document showing that the FTC and Caremark have jointly requested a pause in the ongoing legal proceedings against Caremark so that the FTC can review a proposed settlement agreement that would resolve all claims against Caremark.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 71.56, Change: -1.24, Percent Change: -1.70